Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23572993 | 1.00 | EGFR (0.50) | EGFRSRCNLNMMP8ALDH1A1 | |
| SCHEMBL23573011 | 0.88 | NLN (0.47) | NLN | |
| SCHEMBL21794913 | 0.88 | NLN (0.47) | NLN | |
| SCHEMBL8695020 | 0.88 | NLN (0.41) | EGFRSRCNLN | |
| SCHEMBL23573019 | 0.88 | NLN (0.47) | NLNALDH1A1 | |
| SCHEMBL13073718 | 0.88 | NLN (0.47) | NLN | |
| SCHEMBL21794921 | 0.88 | NLN (0.47) | NLNALDH1A1 | |
| SCHEMBL23573040 | 0.88 | NLN (0.47) | NLNALDH1A1 | |
| Histidine SCHEMBL7864674 | 0.86 | ALPI (0.46) | EGFRSRCALDH1A1 | |
| Histidine SCHEMBL27560188 | 0.86 | ALPI (0.46) | EGFRSRCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999024461-A1 | CLOSTRIDIAL TOXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-05-20 | — | — | WO | claimed |
| US-12331333-B2 | Enhancers of neurolysin activity | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-06-17 | — | — | US | disclosed |
| US-20210198647-A1 | Enhancers of Neurolysin Activity | TEXAS TECH UNIVERSITY SYSTEM | 2021-07-01 | — | — | US | disclosed |
| US-20210198647-A1 | Enhancers of Neurolysin Activity | TEXAS TECH UNIVERSITY SYSTEM | 2021-07-01 | — | — | US | disclosed |
| WO-2020047185-A9 | ENHANCERS OF NEUROLYSIN ACTIVITY | TEXAS TECH UNIVERSITY SYSTEM (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020047185-A1 | ENHANCERS OF NEUROLYSIN ACTIVITY | TEXAS TECH UNIVERSITY SYSTEM (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2011107948-A2 | LIGANDS OF INSULIN DEGRADING ENZYME AND THEIR USES | UNIVERSITE LILLE 2 DROIT ET SANTE (FR) | 2011-09-09 | — | — | WO | disclosed |
| WO-1999024461-A1 | CLOSTRIDIAL TOXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331333-B2 | Enhancers of neurolysin activity | GAP43, NLN, BDNF | EGFR 1761/4885SRC 2450/4885NLN 2/4885 |
| US-20210198647-A1 | Enhancers of Neurolysin Activity | GAP43, NLN, BDNF | EGFR 1761/4885SRC 2450/4885NLN 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.